Table of Contents

State/Territory Name: Michigan

State Plan Amendment (SPA) #: MI 23-0029

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Pages



Financial Management Group

January 17, 2024 Meghan Groen Senior Deputy Director State of Michigan, Department of Community Health 400 South Pine Street Lansing, Michigan 48933

RE: Michigan State Plan Amendment (SPA) 23-0029

Dear Senior Deputy Director Groen:

We have reviewed the proposed amendment to Attachment 4.19-A of your Medicaid state plan submitted under transmittal number (TN) 23-0029 effective for services on or after October 1, 2023. This SPA provides authority to establish hospital reimbursement, separate from the Diagnosis Related Group (DRG) payment, for Spinraza and drugs for which the State has entered CMS approved outcomes-based contract arrangements with drug manufacturers for drugs provided to Medicaid beneficiaries.

We conducted our review of your submittal according to the statutory requirements at sections 1902(a)(2), 1902(a)(13), 1902(a)(30), 1903(a), and 1923 of the Social Security Act and the regulations at 42 CFR 447 Subpart C. We hereby inform you that Medicaid State plan amendment 23-0029 is approved effective October 1, 2023. We are enclosing the CMS-179 and the amended plan pages.

If you have any questions, please call Tom Caughey at (517) 487-8598.

Sincerely,

Rory Howe Director

Enclosure

CENTERS FOR MEDICARE & MEDICAID SERVICES	OMB No. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	1. TRANSMITTAL NUMBER 2. STATE
	23 — 0029 MI
	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL
	SECURITY ACT
TO: CENTER DIRECTOR	4. PROPOSED EFFECTIVE DATE
CENTERS FOR MEDICAID & CHIP SERVICES	October 1, 2023
DEPARTMENT OF HEALTH AND HUMAN SERVICES	
5. FEDERAL STATUTE/REGULATION CITATION 42 CFR 447	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a FFY 2024 \$0
42 61 ((447	b. FFY 2025 \$0
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	8. PAGE NUMBER OF THE SUPERSEDED PLAN
	SECTIONOR ATTACHMENT (If Applicable)
Attachment 4.19A Page 11a	Attackment 4.40. A Dage 44a (TNH 24.0040)
	Attachment 4.19A Page 11a (TN# 21-0010)
9. SUBJECT OF AMENDMENT	
	ent, separate from the Diagnosis Related Group (DRG) payment,
for Spinraza and drugs for which the State has entered CMS	approved outcomes-based contract arrangements with drug
manufacturers for drugs provided to Medicaid beneficiaries.	
10. GOVERNOR'S REVIEW (Check One)	
GOVERNOR'S OFFICE REPORTED NO COMMENT	✓ OTHER, AS SPECIFIED:
COMMENTS OF GOVERNOR'S OFFICE ENCLOSED	
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	
11. SIGNATURE OF STATE AGENCY OFFICIAL	15. RETURN TO
	Rehavioral and Dhysical Llastin and Asing Convisor
12. TYPED NAME	Behavioral and Physical Health and Aging Services Administration
Meghan Groen	Office of Strategic Partnerships & Medicaid Administrative Services – Federal Liaison
13. TITLE	Capitol Commons Center – 7 th Floor
Senior Deputy Director	400 South Pine
14. DATE SUBMITTED	Lansing, Michigan 48933
November 1, 2023	Attn: Erin Black
FOD CMS	USE ONLY
16. DATE RECEIVED	17. DATE APPROVED
November 1, 2023	January 17, 2024
PLAN APPROVED - ONE COPY ATTACHED	
18. EFFECTIVE DATE OF APPROVED MATERIAL	19 SIGNATURE OF APPROVING OFFICIAL
October 1, 2023	
20. TYPED NAME OF APPROVING OFFICIAL	21. TITLE OF APPROVING OFFICIAL
Rory Howe	Director , FMG
22. REMARKS	

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

State of MICHIGAN

Policy and Methods for Establishing Rates Inpatient Hospital

I. Hospital Rapid Whole Genome Sequencing (rWGS) Testing Reimbursement

Rapid whole genome sequencing testing provided in the inpatient hospital setting is excluded from the DRG payment. An additional payment for medically necessary rWGS will be made to a hospital when established clinical criteria is met. Costs associated with rWGS are to be billed separately from the inpatient episode. Hospital reimbursement will be made according to the Medicaid laboratory fee schedule.

J. SPINRAZA

SPINRAZA PROVIDED IN THE INPATIENT HOSPITAL SETTING IS EXCLUDED FROM THE DRG PAYMENT. AN ADDITIONAL PAYMENT FOR MEDICALLY NECESSARY SPINRAZA WILL BE MADE TO A HOSPITAL WHEN ESTABLISHED CLINICAL CRITERIA IS MET. COSTS ASSOCIATED WITH SPINRAZA ARE TO BE BILLED SEPARATELY FROM THE INPATIENT EPISODE. HOSPITAL REIMBURSEMENT WILL BE MADE ACCORDING TO THE MEDICAID FEE SCHEDULE.

K. OUTCOMES-BASED CONTRACT ARRANGEMENTS

DRUGS PROVIDED UNDER OUTCOMES-BASED CONTRACT ARRANGEMENTS WITH DRUG MANUFACTURERS FOR DRUGS PROVIDED TO MEDICAID BENEFICIARIES IN THE INPATIENT HOSPITAL SETTING ARE EXCLUDED FROM THE DRG PAYMENT. AN ADDITIONAL PAYMENT FOR DRUGS UNDER AN OUTCOMES-BASE CONTRACT ARRANGEMENT WILL BE MADE TO A HOSPITAL WHEN ESTABLISHISHED CLINICAL CRITERIA IS MET. COSTS ASSOCIATED WITH THESE DRUGS ARE TO BE BILLED SEPARETLY FROM THE INPATIENT EPISODE. HOSPITAL REIMBURSMENT WILL BE MADE ACCORDING TO THE MEDICAID FEE SCHEDULE.